Creative Planning Buys New Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)

Creative Planning purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 35,799 shares of the company’s stock, valued at approximately $93,000.

A number of other institutional investors have also recently bought and sold shares of ABCL. Intellectus Partners LLC lifted its holdings in AbCellera Biologics by 0.7% during the 2nd quarter. Intellectus Partners LLC now owns 545,533 shares of the company’s stock worth $1,615,000 after purchasing an additional 3,750 shares during the last quarter. Evergreen Capital Management LLC acquired a new stake in shares of AbCellera Biologics during the second quarter worth $32,000. B. Riley Wealth Advisors Inc. boosted its position in shares of AbCellera Biologics by 104.8% in the second quarter. B. Riley Wealth Advisors Inc. now owns 21,500 shares of the company’s stock valued at $64,000 after acquiring an additional 11,000 shares during the period. Squarepoint Ops LLC grew its stake in shares of AbCellera Biologics by 47.3% in the second quarter. Squarepoint Ops LLC now owns 68,908 shares of the company’s stock valued at $204,000 after acquiring an additional 22,132 shares in the last quarter. Finally, Green Alpha Advisors LLC increased its position in AbCellera Biologics by 96.3% during the third quarter. Green Alpha Advisors LLC now owns 48,515 shares of the company’s stock worth $126,000 after acquiring an additional 23,806 shares during the period. Institutional investors and hedge funds own 61.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ABCL. Stifel Nicolaus reissued a “buy” rating and issued a $12.00 price objective (down previously from $14.00) on shares of AbCellera Biologics in a report on Tuesday, November 5th. Benchmark restated a “hold” rating on shares of AbCellera Biologics in a research note on Tuesday, November 5th.

AbCellera Biologics Stock Down 6.0 %

Shares of AbCellera Biologics stock opened at $2.96 on Wednesday. AbCellera Biologics Inc. has a 12-month low of $2.34 and a 12-month high of $6.05. The company has a market capitalization of $874.30 million, a price-to-earnings ratio of -4.95 and a beta of 0.35. The firm’s 50-day moving average price is $2.65 and its two-hundred day moving average price is $3.02.

AbCellera Biologics (NASDAQ:ABCL) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%. The firm had revenue of $6.51 million during the quarter, compared to the consensus estimate of $8.95 million. During the same period last year, the business earned ($0.10) earnings per share. On average, sell-side analysts expect that AbCellera Biologics Inc. will post -0.59 earnings per share for the current year.

AbCellera Biologics Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.